CBS-0550 explained

CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB₂ receptor agonist, with 1400x selectivity for CB₂ over the related CB₁ receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.^[1] A number of related compounds have been developed with similar properties.^[2]

See also

• A-836,339
• SER-601

Notes and References

1. Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T, Tomishima Y, Futaki N, Toda Y, Saito S . 6 . Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action . Bioorganic & Medicinal Chemistry . 16 . 3 . 1111–24 . February 2008 . 18006322 . 10.1016/j.bmc.2007.10.087 .
2. Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, Toda Y, Saito S . 6 . N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability . Bioorganic & Medicinal Chemistry Letters . 17 . 22 . 6299–304 . November 2007 . 17884496 . 10.1016/j.bmcl.2007.09.004 .